Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.98 -1.08 (-4.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Acadia Pharmaceuticals Announces the Rett Sibling Scholarship Program
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Why Acadia Pharmaceuticals Stock Is Rising Today
An analyst upgrade is sparking a rally in the drugmaker's shares today. 
Via The Motley Fool
2 Growth Stocks I'd Buy on the Dip
These two growth stocks could be worthwhile buy-and-holds. 
Via The Motley Fool
Electronic Arts To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Tuesday
JP Morgan increased ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) price target from $29 to $32. JP Morgan analyst Tessa Romero upgraded the stock from Neutral to Overweight. ACADIA Pharmaceuticals shares... 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Analyst Ratings for ACADIA Pharmaceuticals
Via Benzinga
Can This Red-Hot Biotech Stock Keep Beating the Broader Markets?
This biotech stock has been on fire in 2023. 
Via The Motley Fool
Why CarMax Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Bionomics Limited (NASDAQ: BNOX) shares jumped 308% to $4.00 after the company announced the ATTUNE trial met its primary endpoint showing BNC210 treatment led to a statistically significant... 
Via Benzinga
Acadia Pharmaceuticals Appoints Albert Kildani as Senior Vice President, Investor Relations and Corporate Communications
From Acadia Pharmaceuticals Inc.
Via Business Wire
Analyst Expectations for ACADIA Pharmaceuticals's Future
Via Benzinga
ACADIA Pharmaceuticals's Earnings: A Preview
Via Benzinga
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
From Acadia Pharmaceuticals Inc.
Via Business Wire
2 Supercharged Growth Stocks Billionaires Can't Stop Buying
A top hedge fund has been steadily buying these two growth stocks in 2023. 
Via The Motley Fool
This Under-the-Radar Growth Stock Could Soar by 277%, According to Wall Street
This small-cap biotech might be a hidden gem. 
Via The Motley Fool
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
JP Morgan Maintains Neutral Rating for ACADIA Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Acadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals Appoints Kevin R. Oliver, Ph.D., as Senior Vice President, Chief Business Officer
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals to Announce Second Quarter Financial Results on August 2, 2023
From Acadia Pharmaceuticals Inc.
Via Business Wire
Acadia Pharmaceuticals: A Mid-Cap Biotech Making Large Moves
Acadia may experience a profit-taking pullback near-term but the recent high volume gapper and promising pipeline developments bode well for long-term uptrend. 
Via MarketBeat
Nasdaq Drops 50 Points; Wells Fargo Earnings Beat Views
U.S. stocks traded mixed toward the end of trading, with the S&P 500 and Nasdaq Composite moving lower on Friday. The Dow traded up 0.30% to 34,498.91 while the NASDAQ fell 0.36% to 14,087. The S&P... 
Via Benzinga
Reassuring Market Adoption of Daybue Fuels Acadia's Strategic Advancements, Analysts Boost Price Targets
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) expanded its current licensing agreement for trofinetide with Neuren Pharmaceuticals to acquire ex-North American  
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.